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Abstract
Background: HIV viral load (VL) testing is the gold standard for antiretroviral
treatment monitoring, but many barriers exist to VL testing in resource-limited
settings, including storage and transport limitations for whole blood and plasma.
Data from various studies indicate that HIV RNA is stable beyond current
recommendations. We conducted a systematic review to assess stability data of
HIV RNA in whole blood and plasma across times and temperatures.
Methods and Findings: Using a pre-defined protocol, five databases were
searched for studies where blood samples from HIV patients were stored at time
and temperature points that exceeded manufacturer recommendations. RNA
stability, the primary outcome, was measured by the difference in means compared
to samples stored within established thresholds. RNA stability was defined as #0.5
log degradation. The search identified 10,716 titles, of which nine full-text articles
were included for review. HIV RNA maintained stability in EDTA whole blood and
plasma at all measured time points up to 168 hours when stored at 4˚C, while
stability was detected at 72 hours (95% confidence) in whole blood at 25˚C, with
data points before and beyond 72 hours suggesting stability but not reaching
statistical significance. For EDTA plasma stored at 30˚C, stability was maintained
up to 48 hours (95% confidence), with OLS linear regression estimates up to
127 hours, suggesting stability. Overall, quality of studies was moderate.
Limitations included small sample sizes, few studies meeting inclusion criteria, and
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no studies examining RNA stability in low viremia (,3,000 copies/mL)
environments.
Conclusions:Whole blood and plasma samples in EDTA may remain stable under
conditions exceeding current manufacturer recommendations for HIV VL testing.
However, given the limited number of studies addressing this question, especially
at low levels of viremia, additional evaluations on HIV RNA stability in EDTA tubes
and PPT in field conditions are needed.
Introduction
The 2013 WHO HIV treatment guidelines strongly recommend routine viral load
(VL) testing six and twelve months after treatment initiation and then at least
every year thereafter (strong recommendation, low-quality evidence) [1]. VL
testing enables clinicians to monitor the efficacy of antiretroviral therapy and to
identify patients struggling with treatment adherence before they develop
resistance. Identifying elevated VLs early and providing enhanced adherence
support can lead to over 70% of patients successfully re-suppressing HIV viral
replication to undetectable levels [2].
Despite the benefits of VL testing, HIV RNA sample transport constraints limit
testing access in resource-limited settings. It is estimated that only 20% of people
on antiretroviral treatment (ART) in Africa access routine VL testing [3].
For VL testing, samples may be shipped to the laboratory as whole blood,
plasma, or dried blood or plasma spots (DBS/DPS), depending on the resources
available. Optimizing sample collection options depends on the trade-offs
between test accuracy and logistical capacity.
DBS/DPS remain stable over extended time and temperature periods, often
making this the only practical transport option in remote areas. However, the
smaller sample volume reduces sensitivity and the cell-associated nucleic acid can
reduce specificity [4, 5]. For this reason, testing plasma samples is preferred, where
feasible.
Plasma transport with ethylenediaminetetraacetic acid (EDTA) tubes or plasma
preparation tubes (PPT) is the gold standard for VL testing. However, generating
plasma samples requires trained phlebotomists and electricity in health posts to
power the centrifuges. Current recommendations for plasma storage and
transport require that plasma is transported within 24 hours at 25 C˚ in EDTA
tubes, or within 5 days at 4 C˚ for EDTA tubes or PPT, after centrifugation
(Appendix S1) [6]. If there is no access to centrifugation, whole blood in EDTA
tubes or PPT cannot be stored more than 6 hours at 25 C˚. The logistical
constraints, coupled with overall expense, make this option challenging to
implement in resource-limited settings. Although phlebotomists are still required
for venous blood sampling, whole blood transport relieves the need of electricity
for centrifugation in health posts – a requirement 30% of health posts in
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Sub-Saharan Africa lack – as well as potential transcription errors, and safety and
contamination risks, associated with plasma processing [7].
The limited sample transport time and temperature thresholds effectively limit
the radius of whole blood transport to 6 hours at 25 C˚ or to 24 hours at 4 C˚. The
implications of such cautious labelling would not significantly affect care in
developed countries, since maintaining the cold chain is less difficult, and there is
widespread access to centrifuges and efficient specimen transport services.
However, in resource-poor environments, such restrictive guidance on whole
blood and plasma transport greatly limits access to VL testing to only those in
close proximity to national or regional laboratories. This systematic review seeks
to measure HIV RNA stability in EDTA tubes and PPT at extended time and
temperature thresholds, compared to the established thresholds, in all published
studies.
Methods
Using a pre-defined protocol, five databases (Pubmed, EMBASE, Ovid, LILACS,
and Web of Science) were searched according to pre-specified search terms
(Appendix S2). No restrictions on language, publication status, or year of
publication were used. Titles were accessed from database inception to August
13th, 2013 or October 28th, 2013, depending on database.
After an initial title search, selected abstracts were reviewed in duplicate using
piloted forms. Any disagreements were resolved with a third reviewer. The same
procedure was followed for inclusion of full text articles and data extraction.
Articles were included if they measured HIV RNA stability beyond the established
time and temperature thresholds for whole blood or plasma with either EDTA
tubes or PPT. Extracted information included characteristics of the study,
population, intervention, outcome and risk of bias. Recommended time and
temperature thresholds include: ,6 hours at room temperature (defined as 25 C˚)
for whole blood in EDTA tubes or PPT and,24 hours in whole blood in EDTA at
4 C˚. Plasma can be stored for 24 hours at room temperature (defined as 25 C˚) in
EDTA tubes or 5 days at 4 C˚ for EDTA tubes or PPT.
Risk of bias was estimated for each study according to a modified Jadad scale
adapted for basic science [8]. Risk of bias was then summarized according to the
GRADE framework [9, 10].
The primary outcome measured was mean log declines in RNA stability beyond
recommended time and temperature thresholds, with significant declines in RNA
stability reported as a secondary outcome. Data was analyzed by mean VL
differences at different temperature thresholds. Mean and standard errors were
calculated from median and range when not otherwise provided [11]. When not
provided in the study, standard deviation of the difference in means was imputed
using the Cochrane Handbook methodology and the coefficients of correlation
provided among the included studies [12]. Corresponding authors were contacted
for any additional information needed.
HIV RNA Stability beyond Current Storage Thresholds
PLOS ONE | DOI:10.1371/journal.pone.0113813 December 1, 2014 3 / 13
A viral degradation cutoff of . 0.5 log copies/mL was used to define clinical
significance, consistent with the literature [13, 14]. Figures were developed to
chart RNA stability over time by transport type at specific temperature thresholds,
with lines of best fit generated using Stata 13.
Results
The database search yielded 10,716 unique titles (Figure 1); 60 articles were
reviewed in full text and nine studies were taken through for review.
Characteristics of selected studies are outlined in Table 1.
Studies measured RNA degradation in EDTA whole blood (n56)[15–20],
EDTA plasma (n53) [15, 21, 22], and PPT whole blood (n51) [23] (Table 1).
All included studies were controlled studies with matched blood samples drawn
from the same individuals. Populations included ART nai¨ve patients (n54)
[15, 17, 18, 23] and mixed or unspecified treatment populations (n55)
[16, 19–22]. All studies examined RNA stability in the laboratory, rather than field
conditions. Six of the nine studies were published prior to 2000, and all were
conducted in the United States and Europe. Each study reported storage
conditions for both the experimental and control arm.
With regards to risk of bias, according to a modified Jadad scale (Appendix S3),
all studies met the requirements for randomization, with a well-designed and
completed protocol. All blood sources were derived from patients with HIV. The
same diagnostic platforms and processes were used for experimental and control
arms.
EDTA whole blood
For EDTA whole blood, six studies assessed RNA stability at 4 C˚ and room
temperature (25 C˚), with time points at zero, six, 18, 24, 48, 72, and 168 hours
(Table 1). HIV RNA remained stable for all measured time points until 168 hours
at 4 C˚ with 95% confidence [15]. For the EDTA whole blood samples stored at
room temperature (25 C˚) beyond the established stability threshold, four time
points were within the acceptable threshold for RNA stability, and another four
had a point estimate that suggested stability, but the confidence intervals
overlapped the 0.5 log degradation threshold. The latest time point to maintain
statistically significant stability according to the pre-specified criteria was at
72 hours [15]. An additional study at room temperature found that 72.4% of the
samples measured had less than 0.2 log degradation, with 96.5% at less than 0.5
log degradation after 24 hours [18]. The matrix of RNA stability in EDTA whole
blood and plasma over time is indicated in Figure 2.
EDTA plasma
Three studies assessed the stability of RNA in EDTA plasma, at 4 C˚, 22 C˚, 30 C˚
and 37 C˚, with time points at 24, 48, 168, and 336 hours (Table 1). There was
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limited decline in RNA copies/mL at 4 C˚ after 168 hours (0.04 log copies/mL) and
after 336 hours (0.01 log copies/mL), with 95% confidence [15, 21, 22].
At 30 C˚, HIV RNA maintained stability in EDTA plasma until 48 hours (0.12
log reduction). At 168 hours there was a significant decline of 0.74 log copies/mL,
with continued declines at 336 hours (1.6 log copies/mL decline) [15, 21].
Assuming a linear degradation of RNA in these samples, and using Ordinary Least
Squares (OLS) linear regression, the stability threshold was surpassed after
127 hours, though this analysis is limited by the lack of data between 48 and
168 hours and by the fact that there is little data to assume a linear pattern of
degradation under these conditions. After 168 hours at 37 C˚, the difference in
means was 0.92 log copies/mL [22]. At 22 C˚, there was limited (0.03 log copies/
mL) and insignificant decline after 168 hours. Due to insufficient time points at
22 C˚ and 37 C˚, no figures are presented with results from these EDTA samples.
Figure 1. Search Strategy.
doi:10.1371/journal.pone.0113813.g001
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PPT whole blood
Only one study assessed the stability of PPT whole blood. It found a no significant
degradation 30 hours post collection at 25 C˚ [23]. Instead, there was a 137%
increase in the baseline RNA copies/mL.
The studies were evaluated under a GRADE framework and found to be of
moderate quality, owing to the small sample sizes and failure to exclude
publication bias (Appendix S4).
Discussion
Our analysis indicates that HIV RNA is stable in EDTA tubes beyond the current
manufacturer recommendations for time and temperature and highlights the need
for more definitive studies at higher temperatures that may be encountered in
countries with high HIV burdens. For EDTA whole blood transport, RNA remains
stable until 72 hours, with data points at times beyond 72 hours suggesting
Figure 2. RNA degradation in EDTA tubes over time and temperature.
doi:10.1371/journal.pone.0113813.g002
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stability, but with 95% confidence intervals that spanned the stability threshold.
For EDTA plasma at 30 C˚, measures of RNA were within the stability threshold at
48 hours. While a meta-regression suggested stability beyond 48 hours (estimated
stability until 127 hours), no data points were available between 48 and 168 hours
and one cannot assume linear RNA degradation under these conditions. More
data is needed to confirm the true stability of EDTA plasma at 30 C˚ beyond
48 hours. These studies indicate that transport for both EDTA whole blood and
plasma can potentially be greatly expanded, thus increasing the feasibility of
transporting blood tubes to laboratories in resource limited settings.
Acceptable RNA degradation over the course of sample transport needs to be
assessed through the lens of clinical relevance. A VL in whole blood or plasma of
1,000 copies/mL is recommended by the 2013 consolidated WHO HIV treatment
guidelines as the threshold by which to define virological failure [1]. Thus, in
certain cases where VLs fall close to the 1,000 copies/mL threshold, a decline
of.0.5 log in RNA stability may lead to incorrect clinical management decisions.
According to a multi-country VL assessment of 21,909 adults, only 4.4% had VL
results between 1,000–5,000 copies/mL in routine VL testing, with an even smaller
percentage falling within 0.5 log of the failure threshold [24]. Further clarity on
acceptable thresholds for degradation is needed, particularly at lower (,3,000
copies/mL) VL values. In our analysis, we considered declines of greater than 0.5
log copies/mL to be clinically relevant, consistent with the literature.
The precedent for expanded sample transport thresholds have already been set
by the British HIV Association. In their 2011 guidelines for routine monitoring,
EDTA whole blood storage for 2–3 days at room temperature is recommended,
with evidence cited from at least one well-designed quasi-experimental study [25].
However, this recommendation would not account for temperatures over 30 C˚,
which are rarely seen in the UK, but are frequent in many low- and middle-
income countries.
Adapting sample transport regulations to match the demonstrated HIV RNA
stabilities would enable VL sample collection to expand and reach more people
living with HIV. A one-week sample transport window would allow for bi-weekly
or weekly sample collection, provided samples were kept at 25 C˚, as might be
possible with passive cooling devices, such as a cooler box.
Countries implementing VL testing in resource–limited settings will need
guidance on acceptable time and temperature thresholds for sample transport,
particularly in hot climates. Given that the studies included in this systematic
review indicate that stability at extended time and temperature thresholds is
greater than current recommendations indicate, we recommend that suppliers of
EDTA tubes and PPT, as well as viral load tests, urgently undertake the necessary
studies to allow for more flexible sample transport recommendations.
Limitations
Some of these studies are not sufficiently powered to assess significance at 95%
confidence at particular timepoints. Much of this variability may be attributed to
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variation across viral loads in patient samples, rather than over time. As only
aggregate data was available, a matched pair comparison of differences in HIV
RNA stability over time was not possible, thus confidence intervals around the
point estimates are conservative estimates.
The majority of included studies were published prior to 2000 and the Roche
Amplicor HIV-1 Monitor was the most utilized VL assay. While the age of these
studies would not impact the RNA stability, newer VL technologies may better
detect RNA and could narrow the RNA degradation gap. Our study did not
incorporate the variability in precision between VL assays, although these have
been documented [26]. For example, the new Roche COBAS Ampliprep/COBAS
TaqMan HIV-1 v2.0 assay has been reported to overestimate HIV RNA levels in
plasma compared to other technologies [26]. Most studies were adequately
powered to account for these low-magnitude variations.
These studies were laboratory-based, rather than examining the field impacts of
sample transport beyond time and temperature thresholds, with only one study
examining PPT transport. Given the logistical constraint of centrifugation, the
added value of PPT may be limited if whole blood remains stable in EDTA tubes
for extended periods. Additionally the inconsistent assessments of time and
temperature thresholds limited comparability across studies.
The impact of sample transport conditions on low and undetectable VLs need
to be further examined. The majority of people in these studies had VLs over 3.5
log copies/mL with some not receiving ART. Populations accessing VL
monitoring today are generally receiving ART, and VLs in these populations are
lower than those not on ART [1]. A 2010 systematic review of virological
suppression in adults in sub-Saharan Africa found that 78% had virologically
suppressed after 6 months, 76% after 12 months and 67% after 24 months of
treatment [27]. While adherence is generally lower among adolescents and young
adults, a recent systematic review found that adherence was 84% (95% CI
79–89%) in this population in Sub-Saharan Africa [28]. Assessments of HIV RNA
stability drawn from these largely undetectable and low viremia populations will
be needed for insights on RNA stability at low levels and the potential impact of
even minor RNA degradation on clinical decision-making for these populations.
This systematic review examined RNA stability over time and temperature, but it
did not examine increases in HIV RNA past time and temperature thresholds.
Extended storage time may erroneously detect intracellular viral particles after cell
lysis, which is of unknown clinical significance [29]. Given this theoretical risk, and
the lack of studies particularly for patients with undetectable VLs, we caution
generalization of our findings to this population. Further studies are warranted to
establish the safety of extended storage conditions when monitoring patients on ART.
Conclusions
All published studies show that HIV RNA has an extended time and temperature
stability compared to current product labelling. Further studies are needed to
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determine the precise threshold of expansion and to correlate possible time and
temperature-induced increases on HIV RNA at low VLs, especially with the
newest VL technologies. This information is urgently needed in order to revise
sample transport guidelines and facilitate the expansion of HIV VL monitoring in
low- and middle-income countries.
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